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Background: Indacaterol is a novel, inhaled once-daily ultra-long-acting β2-agonist for the 
treatment of chronic obstructive pulmonary disease (COPD).
Objectives: This study compared the onset of action of single doses of indacaterol 150 and 
300 µg with salbutamol 200 µg, salmeterol-fluticasone 50/500 µg, and placebo in moderate-
to-severe COPD patients.
Methods: This was a multicenter, randomized, double-blind, placebo-controlled crossover 
study. The primary variable was forced expiratory volume in one second (FEV1) at five minutes 
postdose.
Results: Out of 89 patients randomized (mean age 62 years), 86 completed the study. At five 
minutes postdose, both indacaterol doses were statistically and clinically superior to placebo 
(P , 0.001), with treatment–placebo differences in FEV1 of 100 (95% confidence interval 
[CI] 70–130) mL and 120 (95% CI 90–150) mL for indacaterol 150 and 300 µg, respectively. 
FEV1 at five minutes postdose with both indacaterol doses was numerically higher than for 
salbutamol (10 and 30 mL for indacaterol 150 and 300 µg, respectively) and significantly 
higher than for salmeterol-fluticasone (50 mL, P = 0.003; 70 mL, P , 0.001, respectively). 
Moreover, both indacaterol doses showed significantly higher FEV1 than placebo (P , 0.001) 
at all postdose time points. The numbers of patients with an FEV1 increase of at least 12% and 
200 mL at five minutes postdose were 16 (18.8%), 24 (27.6%), 20 (23.3%), 8 (9.1%), and 3 
(3.4%) for indacaterol 150 and 300 µg, salbutamol 200 µg, salmeterol-fluticasone 50/500 µg, 
and placebo, respectively.
Conclusions: Single doses of indacaterol 150 and 300 µg demonstrated a fast onset of action 
similar to that for salbutamol and faster than that for salmeterol-fluticasone.
Keywords: indacaterol, onset of action, chronic obstructive pulmonary disease
Introduction
Chronic obstructive pulmonary disease (COPD), being a condition associated with 
increased morbidity and mortality, causes a substantial and increasing burden to soci-
ety in many countries.1,2 The Global Initiative for Chronic Obstructive Lung Disease 
(GOLD) guideline3 recommends regular use of bronchodilators for symptomatic 
management of COPD, including inhaled β2-agonists and anticholinergics.3 As with 
all chronic diseases, nonadherence to treatment is common in patients with COPD, 
potentially leading to adverse health outcomes and reduced quality of life.4 Character-
istics of COPD medications and regimens may often contribute to nonadherence, and 
therefore should be considered when selecting the appropriate treatment for a patient. 
In general, more complex regimens result in suboptimal adherence,5 with frequency 
of dosing regarded as one of the principal factors that negatively affect adherence.6 International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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In addition, adherence is lower for medications that do not 
have an immediate effect on symptoms.7
Indacaterol is a novel, inhaled once-daily ultra-long-
acting β2-agonist (LABA)8 for the treatment of COPD. In 
preclinical studies, the onset of action of indacaterol was 
similar to that of salbutamol and of formoterol, and was 
significantly faster than that of salmeterol.9 In previous 
clinical studies, indacaterol has demonstrated 24-hour 
bronchodilation on once-daily dosing, along with a good 
overall safety and tolerability profile.10–12 The present study 
was conducted to evaluate the onset of action of single doses 
of indacaterol 150 and 300 µg in comparison with that of 
salbutamol 200 µg (the standard “fast-onset” bronchodilator), 
the combination of salmeterol 50 µg and fluticasone 500 µg 
(salmeterol-fluticasone 50/500 µg), and placebo in patients 
with moderate-to-severe COPD.
Methods
This was an international, multicenter, randomized, double-
blind, placebo-controlled, crossover, single-dose study. 
Institutional review board or independent ethics committee 
approval was obtained from each participating study center. 
The study was conducted in accordance with the Declaration 
of Helsinki (1989) and local applicable laws and regulations. 
All patients provided written informed consent prior to par-
ticipation in the study.
study population
Patients of either gender, aged $40 years, with moderate-
to-severe COPD (according to the GOLD 2005 guideline), 
smoking history of $20 pack years, postbronchodilator 
forced expiratory volume in one second (FEV1) $30% but 
,80% of the predicted normal value, and postbronchodilator 
FEV1/forced vital capacity (FVC) ,70% were eligible for 
enrolment in the study.
Patients were excluded from the study if they had any 
concomitant pulmonary disease, type I diabetes or uncon-
trolled type II diabetes, uncontrolled hypertension, unstable 
ischemic heart disease, or malignancy. Patients who had a 
history of asthma, had been hospitalized for a COPD exac-
erbation within six weeks prior to screening or during the 
run-in period, or had experienced respiratory tract infection 
within six weeks prior to screening, were also excluded.
The following medications were prohibited at any time 
during the study (the minimum washout period is shown 
in brackets): long-acting anticholinergics (seven days), 
short-acting anticholinergics (eight hours), fixed-dose 
combination of a β2-agonist and an inhaled corticosteroid 
(ICS, 48 hours), fixed-dose combination of a short-acting 
β2-agonist and a short-acting anticholinergic (eight hours), 
other LABAs (48 hours), short-acting β2-agonists (other 
than those prescribed in the study, six hours), xanthine 
derivatives (one week), and parenteral or oral corticoster-
oids (one month). Patients on fixed-dose combinations of a 
β2-agonist and an ICS were to be switched to the equivalent 
ICS prior to the runin period, with the dose and dosage 
regimen to remain unchanged for the duration of the study. 
Patients on ICS at the screening visit were to continue ICS 
for the duration of the study, again at a dose and regimen 
to remain unchanged.
study design and treatments
The study comprised a prescreening visit, a 14-day screen-
ing/run-in period, and five single-dose treatment periods. 
During the prescreening visit, patients’ ongoing COPD 
medications were reviewed and, if necessary, any pro-
hibited medication was adjusted to an allowable COPD 
therapy. After the screening visit, patients entered into a 
14-day run-in period, during which their eligibility was 
assessed. At baseline, patients were randomized equally 
(using a validated automated system) to one of five treat-
ment sequences to receive indacaterol 150 µg and 300 µg 
delivered via a single-dose dry powder inhaler, salbutamol 
200 µg via the manufacturer’s proprietary multidose dry 
powder inhaler, salmeterol-fluticasone 50/500 µg fixed-
dose combination via the manufacturer’s proprietary 
multidose dry powder inhaler, and placebo. Each treat-
ment sequence comprised five double-blind, single-dose 
treatment periods, with treatment periods separated by 
a 4- to 7-day washout period. At 4–7 days after the last 
treatment visit, patients were contacted by telephone for 
a study completion call.
Patients inhaled through three different devices on each 
visit (one inhalation from a single-dose dry powder inhaler 
and one from each of the two multidose dry powder inhal-
ers used in the study), with the order of devices randomly 
assigned at the start of the study. Treatment allocation was 
concealed from the patients, investigating staff, and the 
clinical trial team by the use of matching placebo inhalers 
all identical in packaging, labeling, and schedule of admin-
istration. An unblinded pharmacist (or designee) prepared 
the individual patient-specific packs from supplied bulk 
medication. Salbutamol was the only rescue medication 
permitted throughout the study, although visits had to be 
rescheduled if salbutamol was taken within six hours prior 
to the start of the visit.International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
313
Onset of action of indacaterol in COPD patients
Assessments and outcomes
Efficacy
All efficacy evaluations were based on spirometric assess-
ment of lung function, performed at 50 and 15 minutes 
predose and at 5, 15, and 30 minutes, and at 1 and 2 hours 
postdose. The postdose time was measured from the time the 
first device was used at each study visit (the three devices 
were used in a randomized order, as described above). 
All spirometry equipment and spirometric testing were in 
accordance with the American Thoracic Society/European 
Respiratory Society standards.13
The primary efficacy variable was FEV1 at five minutes 
postdose. The primary objective was to compare indacaterol 
150 and 300 µg and placebo in terms of FEV1 at five min-
utes postdose. The secondary objectives were to compare 
indacaterol 150 and 300 µg with salbutamol 200 µg and 
salmeterol-fluticasone 50/500 µg, and to compare salmeterol-
fluticasone 50/500 µg with salbutamol 200 µg in terms of 
FEV1 at five minutes postdose. The other efficacy variables 
were FEV1 at other scheduled time points; the proportion of 
patients with at least 10%, 12%, and 15% increase in FEV1 
from baseline to each scheduled time point; and the propor-
tion of patients with at least a 12% and 200 mL increase in 
FEV1 from baseline to each scheduled time point.
safety
Safety assessments included recording of adverse events 
and serious adverse events, along with evaluation of their 
severity, duration, and relationship to study drug. In addition, 
samples were collected for hematology and blood chemistry 
(including serum potassium and blood glucose), and vital 
signs and electrocardiogram assessments were recorded.
sample size calculation  
and statistical analysis
It was estimated that 53 patients were needed to complete 
the study, assuming a difference of 120 mL between each 
indacaterol dose and placebo in terms of FEV1 at five min-
utes postdose, a standard deviation of 240 mL, a two-sided 
significance level of 5% (adjusted to 2.5% using a Bonferroni 
correction for the two main treatment comparisons, that is, 
indacaterol [150 and 300 µg] versus placebo), and a power 
of 90%. As there were five treatment sequences and six 
inhaler orders for individual treatment sequences, a total of 
60 patients with evaluable measurements were required in 
order to have an equal number of patients per inhaler order 
and per treatment sequence. Allowing for a 15% dropout 
rate and with the number inflated to ensure balance across 
the treatment sequences, it was calculated that 75 patients 
needed to be randomized.
The primary efficacy analysis was performed on a modi-
fied intent-to-treat population that included all randomized 
patients who received at least one dose of study drug (the 
modification was that patients were analyzed according to 
treatment received in each treatment period). The safety 
population, which was used in the analysis of all safety 
variables, included all patients who received at least one 
dose of study drug.
The primary efficacy variable, FEV1 at five minutes 
postdose, was analyzed using a mixed model, with treat-
ment group and period modeled as fixed effects, patient as 
a random effect, and period baseline FEV1 as a covariate. 
Period baseline FEV1 was defined as the average of the 
FEV1 values measured 50 and 15 minutes prior to study 
drug administration in each treatment period. For the pri-
mary variable, estimated least squares means and treatment 
differences with associated 95% confidence intervals (CIs) 
are presented. A multiplicity adjustment for the two main 
treatment comparisons in the study was made using a step-
down Dunnett’s test implemented in a closed test procedure. 
Similar mixed-effect models were used to analyze FEV1 at 
the other time points.
The proportion of patients with at least a 10%, 12%, and 
15% increase in FEV1 from baseline at each scheduled time 
point, and the proportion of patients with at least a 12% and 
200 mL increase in FEV1 from baseline at each scheduled 
time point, were summarized using descriptive statistics 
and analyzed by logistic regression for each time point. The 
logistic regression model included terms for period, treat-
ment, and period baseline as fixed effects and patient as a 
random effect. The estimated odds ratios are presented along 
with the associated 95% CIs and P values. All analyses were 
performed using SAS statistical software (version 9.1.3 for 
Windows; SAS Institute Inc., Cary, NC).
Results
Patient disposition, demographics,  
and baseline characteristics
Of 114 patients screened, 89 were eligible to participate in 
the study. All eligible patients were randomized to treatment 
sequences, and no patient received the study drug in error; 
thus, the safety population was identical to the modified 
intent-to-treat population. Eighty-six (96.6%) patients com-
pleted the study, while three (3.4%) patients discontinued 
from the study (one each due to withdrawal of consent, loss 
to follow-up, and protocol deviation).International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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Table 1 Demographic summary and baseline clinical characteristics 
(safety population)
Variable Total, n = 89
Age (years)
  Mean ± sD 62.3 ± 8.37
  range 43–79
sex, n (%)
  Male 54 (60.7)
  Female 35 (39.3)
race, n (%)
  Caucasian 88 (98.9)
  Black 1 (1.1)
Weight (kg)
  Mean ± sD 80.1 ± 17.27
  range 49.0–120.0
Duration of COPD (years)
  Mean ± sD 6.8 ± 5.81
  range 0.1–27.0
ICs use, n (%)
  Yes 49 (55.1)
  no 40 (44.9)
COPD medication discontinued prior  
to start of study treatment, n (%)
  Long-acting anticholinergic 31 (34.8)
  β2-agonist plus steroid 28 (31.5)
  Long-acting β2-agonist 23 (25.8)
  β2-agonist plus anticholinergic 14 (15.7)
  Xanthine 9 (10.1)
  short-acting anticholinergic 4 (4.5)
smoking history, n (%)
  exsmoker 40 (44.9)
  smoker 49 (55.1)
Postbronchodilator FeV1 (L) at screening
  Mean ± sD 1.48 ± 0.420
  range 0.77–2.60
Postbronchodilator FVC (L) at screening
  Mean ± sD 2.94 ± 0.851
  range 1.21–5.24
Postbronchodilator FeV1 (% predicted) at screening
  Mean ± sD 53.5 ± 12.73
  range 31.6–83.8
Postbronchodilator FeV1/FVC at screening (%)
  Mean ± sD 51.4 ± 9.08
  range 27.4–68.8
FeV1 reversibility (% increase) at screening
  Mean ± sD 9.1 ± 12.22
  Median 6.1
  25th–75th quartile 0.9–16.5
  range -22.8 – 41.0
Note: FeV1 reversibility at screening was measured 15–30 minutes after inhalation 
of 400 µg salbutamol.
Abbreviations: sD, standard deviation; ICs, inhaled corticosteroids; FeV1, forced 
expiratory  volume  in  one  second;  FVC,  forced  vital  capacity;  COPD,  chronic 
obstructive pulmonary disease.
Demographic and baseline clinical characteristics are 
  summarized in Table 1. More than half of the patients (61.8%) 
were aged ,65 years, the majority was Caucasian, and more than 
half were male. All patients were current or former smokers.
Efficacy
For the primary efficacy variable (FEV1 at five minutes 
postdose), the least squares mean values for indacaterol 150 
and 300 µg were higher than that for placebo by 100 and 
120 mL, respectively (P , 0.001, Figures 1 and 2). Both 
indacaterol doses showed a numerically higher FEV1 at five 
minutes postdose than salbutamol (differences of 10 and 
30 mL for indacaterol 150 and 300 µg, respectively, versus 
salbutamol, Figure 2). Moreover, both indacaterol doses 
produced significantly higher FEV1 at five minutes postdose 
than salmeterol-fluticasone (50 mL, P = 0.003 and 70 mL, 
P , 0.001, Figure 2).
Serial measurements of FEV1 at all postdose time points 
are shown in Figure 3. Both indacaterol doses showed signifi-
cantly higher FEV1 than placebo (P , 0.001) at all postdose 
time points, significantly higher than salmeterol-fluticasone 
(P , 0.05) at five and 15 minutes postdose, and numerically 
(150 µg) or statistically (300 µg) higher than salmeterol-
fluticasone at 30 minutes postdose (Figure 4). The difference 
between indacaterol 300 µg and salbutamol was statistically 
significant at two hours postdose (P , 0.001).
The proportion of patients with at least a 10%, 12%, 
or 15% increase in FEV1 from baseline at five minutes 
postdose was higher in both indacaterol groups compared 
with salmeterol-fluticasone (P , 0.01), and similar to 
salbutamol (Table 2). At 30 minutes postdose, the propor-
tion of patients with at least a 10%, 12%, or 15% increase 
in FEV1 was higher in both indacaterol groups compared 
with placebo, with the proportions in the indacaterol 300 µg 
group higher than those in the salmeterol-fluticasone group 
(Table 3). The proportion was also higher in both inda-
caterol groups than placebo at five and 15 minutes, and 
at one and two hours postdose (P , 0.001 for all). The 
proportions of patients with at least a 12% and 200 mL 
increase in FEV1 from baseline at five minutes postdose in 
the indacaterol 150 µg, indacaterol 300 µg, and salbutamol 
200 µg groups were higher than that in the salmeterol-
fluticasone 50/500 µg and placebo groups (P , 0.05 for 
all, Figure 5).
safety
Overall, adverse events were reported in 3/86 (3.5%), 3/87 
(3.4%), 4/86 (4.7%), 6/88 (6.8%), and 4/87 (4.6%) patients 
taking indacaterol 150 µg, indacaterol 300 µg, salbutamol 
200 µg, salmeterol-fluticasone 50/500 µg, and placebo, 
respectively. All reported adverse events were mild or moder-
ate in severity, and none were suspected of being related to 
study drug. There were no deaths or serious adverse events International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
Dovepress 
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during this study. No patient discontinued from the study 
due to adverse events. Notably, high pulse rate (.90 beats 
per minute) and systolic blood pressure (.140 mmHg) were 
more frequently reported for patients taking placebo than 
for those taking indacaterol. No patient in the study had an 
absolute corrected QT (Fridericia’s) value of .500 msec 
or a change from baseline of 60 msec. Furthermore, no 
patient had newly occurring or worsening clinically nota-
ble values for serum potassium (minimum postbaseline 
value ,3.0 mmol/L) during this study, and only three patients 
(one patient each who took indacaterol 150 and 300 µg and 
salmeterol-fluticasone 50/500 µg) had newly occurring or 
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Figure 1 Least squares mean FeV1 ± standard error of the mean at five minutes postdose.
Note: Differences versus placebo significant at **P , 0.01 and ***P , 0.001.
Abbreviations: Ind, indacaterol; Ls, least squares; PBO, placebo; salb, salbutamol; s + F, salmeterol-fluticasone.
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worsening of clinically notable values for blood glucose 
(maximum postbaseline value .9.99 mmol/L).
Discussion
As with many chronic conditions, adherence to treatment 
is low in COPD, which is perhaps a reflection of the high 
rate of comorbid conditions and consequent polypharmacy. 
Although indacaterol is being developed for maintenance 
treatment of COPD, and not as rescue medication, fast onset 
on the first dose may help patients perceive an immedi-
ate symptomatic benefit. This, together with the sustained 
24-hour duration of bronchodilation14 and a good overall 
safety and tolerability profile,12 which have been observed 
in other indacaterol clinical studies, may lead to improved 
patient adherence.15
This study was therefore designed to compare the onset 
of action of single doses of indacaterol 150 and 300 µg 
with salbutamol, salmeterol-fluticasone, and placebo. The 
study was conducted as planned, with 96.6% of random-
ized patients completing their assigned treatments. This 
study achieved all primary and secondary objectives. For 
the primary efficacy variable (FEV1 at five minutes post-
dose), both indacaterol doses were superior to placebo, 
with treatment–placebo differences of 100 and 120 mL for 
the 150 and 300 µg doses, respectively. Such differences 
(ie, $100 mL) have been described as ones that patients 
can perceive, and therefore can be considered clinically 
relevant.16 Furthermore, the bronchodilator efficacy of 
both indacaterol doses at this time point was similar to that 
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Table 2 number and proportion of patients with at least 10%, 
12%, or 15% increase in FeV1 at five minutes postdose
Percentage increase in FEV1 n (%)
10% 12% 15%
Indacaterol 
150 µg
35 (41.2)***  ††† 24 (28.2)***  †† 17 (20.0)***  ††
Indacaterol 
300 µg
49 (56.3)***  ‡‡  †††  ¶ 40 (46.0)***  ††† ¶¶ 31 (35.6)***  ‡ ††† ¶¶¶
salbutamol 35 (40.7)***  ††† 31 (36.0)***  ††† 21 (24.4)***  †††
salmeterol-
fluticasone
15 (17.0)* 12 (13.6) 8 (9.1)
Placebo 6 (6.8) 5 (5.7) 3 (3.4)
Notes: *P , 0.05; ***P , 0.001 versus placebo;  ‡P , 0.05;  ‡‡P , 0.01 versus 
salbutamol; ††P , 0.01; †††P , 0.001 versus salmeterol-fluticasone; ¶P , 0.05; ¶¶P , 
0.01; ¶¶¶P , 0.001 versus indacaterol 150 µg. 
Abbreviations: n, number of patients who achieved an improvement; FeV1, forced 
expiratory volume in one second.
Table 3 number and proportion of patients with at least 10%, 
12%, or 15% increase in FeV1 at 30 minutes postdose
Percentage increase in FEV1 n (%)
10% 12% 15%
Indacaterol  
150 µg
39 (45.9)***  33 (38.8)***  26 (30.6)*** 
Indacaterol  
300 µg
51 (58.6)***  ††  ¶  46 (52.9)***  †† ¶ 38 (43.7)***  ††† ¶
salbutamol 48 (55.8)***  † 43 (50.0)***  † 33 (38.4)***  †
salmeterol- 
fluticasone
37 (42.0)*** 32 (36.4)*** 23 (26.1)***
Placebo 16 (18.4) 12 (13.8) 9 (10.3)
Notes: ***P , 0.001 versus placebo; †P , 0.05; ††P , 0.01; †††P , 0.001 versus 
salmeterol-fluticasone; ¶P , 0.05 versus indacaterol 150 µg.
Abbreviations: n, number of patients who achieved an improvement; FeV1, forced 
expiratory volume in one second.
observed with salbutamol, the ‘gold standard’ fast-acting 
rescue medication. Both indacaterol doses were statistically 
superior to placebo for the four other measures of onset of 
action, ie, the proportion of patients with at least a 10%, 
12%, or 15% increase from baseline, or at least a 12% and 
200 mL increase from baseline. The bronchodilator efficacy 
was at least as good as salbutamol for all of these endpoints, 
with the higher indacaterol dose (300 µg) reaching statisti-
cal significance versus salbutamol for some endpoints.
The second active comparator selected for this study 
was the fixed-dose combination of salmeterol and flutica-
sone. Both indacaterol doses demonstrated a faster onset of 
action than salmeterol-fluticasone, with treatment–placebo 
differences in FEV1 at five minutes postdose of 50 mL with 
salmeterol-fluticasone, compared with the 100–120 mL seen 
with indacaterol. In other studies, the combination of salme-
terol and fluticasone has been shown to provide better efficacy 
(even after a single dose) than salmeterol alone.17 It is notable, 
therefore, that in the current study in addition to faster onset 
of action, both indacaterol doses demonstrated bronchodila-
tor efficacy at least as good as salmeterol-fluticasone for the 
remainder of the two-hour assessment period.
There was a low incidence of adverse events, all of which 
were mild or moderate in severity and not suspected of being 
related to the study drug, as expected in a single-dose study. 
There were no deaths or discontinuations due to adverse 
events. There were no serious adverse events or significant 
adverse events reported and no clinically meaningful differ-
ences between the treatments with respect to the numbers 
and types of adverse events reported. The overall safety data 
collected indicate that single doses of indacaterol 150 and 
300 µg have a good overall safety profile.
Conclusion
Single doses of indacaterol 150 and 300 µg demonstrated a 
fast onset of action, similar to that of salbutamol and faster 
than that of salmeterol-fluticasone.
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